CA2962798C - Inhibitors of lactate transporters for use in the treatment of inflammatory diseases - Google Patents

Inhibitors of lactate transporters for use in the treatment of inflammatory diseases Download PDF

Info

Publication number
CA2962798C
CA2962798C CA2962798A CA2962798A CA2962798C CA 2962798 C CA2962798 C CA 2962798C CA 2962798 A CA2962798 A CA 2962798A CA 2962798 A CA2962798 A CA 2962798A CA 2962798 C CA2962798 C CA 2962798C
Authority
CA
Canada
Prior art keywords
cells
lactate
slc5a12
antibody
slc16a1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2962798A
Other languages
English (en)
French (fr)
Other versions
CA2962798A1 (en
Inventor
Claudio MAURO
Robert Haas
Federica MARELLI-BERG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Birmingham
Original Assignee
University of Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Birmingham filed Critical University of Birmingham
Publication of CA2962798A1 publication Critical patent/CA2962798A1/en
Application granted granted Critical
Publication of CA2962798C publication Critical patent/CA2962798C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
CA2962798A 2014-10-20 2015-10-20 Inhibitors of lactate transporters for use in the treatment of inflammatory diseases Active CA2962798C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1418626.6A GB201418626D0 (en) 2014-10-20 2014-10-20 Method
GB1418626.6 2014-10-20
PCT/GB2015/053125 WO2016063037A1 (en) 2014-10-20 2015-10-20 Inhibitors of lactate transporters for use in the treatment of inflammatory diseases

Publications (2)

Publication Number Publication Date
CA2962798A1 CA2962798A1 (en) 2016-04-28
CA2962798C true CA2962798C (en) 2024-04-16

Family

ID=52013297

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2962798A Active CA2962798C (en) 2014-10-20 2015-10-20 Inhibitors of lactate transporters for use in the treatment of inflammatory diseases

Country Status (6)

Country Link
US (3) US20170355987A1 (enExample)
EP (1) EP3209328B1 (enExample)
JP (1) JP6767647B2 (enExample)
CA (1) CA2962798C (enExample)
GB (1) GB201418626D0 (enExample)
WO (1) WO2016063037A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3735427A4 (en) * 2018-01-05 2021-09-15 Immunext Inc. ANTI-MCT1 ANTIBODIES AND ASSOCIATED USES
CA3180476A1 (en) * 2020-05-29 2021-12-02 Robert B. Darnell Markers and cellular antecedents of rheumatoid arthritis flares
CN115300627B (zh) * 2021-05-08 2024-01-26 中南大学湘雅医院 钠-葡萄糖共转运蛋白2抑制剂的应用、一种药物组合物及其应用
TWI842088B (zh) * 2021-09-14 2024-05-11 美商伊穆諾米塔博立森發展公司 人類單羧酸鹽轉運蛋白1抗體及其用途
CN117430697A (zh) * 2022-07-21 2024-01-23 佰舟生物科技(苏州)有限公司 抗mct1抗体及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072746A1 (en) * 2001-10-16 2004-04-15 Michael Sullivan Inhibitors of monocarboxylate transport
WO2010089580A1 (en) * 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
GB201016494D0 (en) 2010-09-30 2010-11-17 Queen Mary Innovation Ltd Polypeptide
KR20120123748A (ko) * 2011-04-29 2012-11-12 원광대학교산학협력단 플로레틴을 포함하는 글루타치온 ｓ―전이효소 유도 및 사이토크롬 ｐ450 효소 억제용 조성물

Also Published As

Publication number Publication date
JP6767647B2 (ja) 2020-10-14
WO2016063037A1 (en) 2016-04-28
US20210087561A1 (en) 2021-03-25
JP2017532332A (ja) 2017-11-02
US20190106697A1 (en) 2019-04-11
US20170355987A1 (en) 2017-12-14
EP3209328A1 (en) 2017-08-30
GB201418626D0 (en) 2014-12-03
EP3209328B1 (en) 2021-09-01
CA2962798A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
US20210087561A1 (en) Inhibitors Of Lactate Transporters For Use In The Treatment Of Inflammatory Diseases
KR102229873B1 (ko) 면역 반응의 향상
JP2023093469A (ja) 抗ｃｄ１６ａ抗体のサイトカインとの組み合わせ
JP2024105466A (ja) Ｉｌ－１１抗体
RS63101B1 (sr) Interleukin-21 muteini i metode lečenja
JP2022501428A (ja) 抗ｌｉｌｒｂ２抗体およびその使用の方法
KR20190035714A (ko) 치료 폴리펩티드의 위형된 종양용해성 바이러스 전달
CA3013333A1 (en) Antibodies having specificity for btla and uses thereof
JP2020517913A (ja) Ｃｄ８０細胞外ドメインポリペプチドによる治療方法
US20220112283A1 (en) Antibodies specific to human nectin-2
US20200281977A1 (en) Nk or t cells and uses thereof
CA3179348A1 (en) Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
권희성 A bispecific antibody targeting tumor necrosis factor-α (TNF-α) and OX40 ligand (OX40L) demonstrates superior efficacy in the treatment of rheumatoid arthritis
RU2820275C2 (ru) Антитела, специфичные в отношении нектина-2 человека
WO2024097641A2 (en) Methods of treating a tumor
JP2024544518A (ja) 癌治療のためのｔｌｒ７アゴニストおよび組合せ
CN117957253A (zh) 癌症的组合治疗中针对cd40和cd137的多特异性结合剂
EA045300B1 (ru) Комбинация антитела против cd16a с цитокином
Sorensen Mechanisms of Vascular and Immune Alteration via Local Cytokine Treatment of Melanoma
JP2018525029A (ja) ミオシン１８ａに対する特異性を有する抗体およびその使用
HK1213791B (en) Enhancement of the immune response

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201005

EEER Examination request

Effective date: 20201005

EEER Examination request

Effective date: 20201005

EEER Examination request

Effective date: 20201005

EEER Examination request

Effective date: 20201005

EEER Examination request

Effective date: 20201005

EEER Examination request

Effective date: 20201005

EEER Examination request

Effective date: 20201005